InvestorsHub Logo
Followers 45
Posts 52524
Boards Moderated 4
Alias Born 05/05/2003

Re: None

Tuesday, 04/20/2021 3:24:52 PM

Tuesday, April 20, 2021 3:24:52 PM

Post# of 486911
#4: THE "DATA GAPS" SUBMITTED TO THE FDA BY THE VACCINE MAKERS

When vaccine makers submitted their papers to the FDA for the Emergency Use Authorization (Note: An EUA is not the same as a full FDA approval), among the many "Data Gaps" they reported was that they have nothing in their trials to suggest they overcame that pesky problem of Vaccine Enhanced Disease.

They simply don't know--i.e. they have no idea if the vaccines they've made will also produce the same cytokine storm (and deaths) as previous attempts at such products.

As Joseph Mercola points out...

"Previous attempts to develop an mRNA-based drug using lipid nanoparticles failed and had to be abandoned because when the dose was too low, the drug had no effect, and when dosed too high, the drug became too toxic. An obvious question is: What has changed that now makes this technology safe enough for mass use?"


If that's not alarming enough, here are other gaps in the data--i.e. there is no data to suggest safety or efficacy regarding:

Anyone younger than age 18 or older than age 55

Pregnant or lactating mothers

Auto-immune conditions

Immunocompromised individuals

No data on transmission of covid

No data on preventing mortality from covid

No data on duration of protection from covid


Hard to believe right?

In case you think I'm making this up, or want to see the actual documents sent to the FDA by Pfizer and Moderna for their Emergency Use Authorization, you can check out this, or this respectively. The data gaps can be found starting with page 46 and 48 respectively.

For now let's turn our eyes to the raw data the vaccine makers used to submit for emergency use authorization.

https://www.deconstructingconventional.com/post/18-reason-i-won-t-be-getting-a-covid-vaccine

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.